Compass Therapeutics, Inc. 2022 Form 10-K Summary
Business Context and Reporting Period
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing antibody-based cancer therapies. This Form 10-K covers the fiscal year ended December 31, 2022, rather than a standalone fourth-quarter report. The company has no approved products and has never generated revenue from product sales.
- Lead programs: CTX-009, a DLL4 x VEGF-A bispecific antibody; CTX-471, a CD137 agonist antibody; and CTX-8371, a preclinical PD-1 x PD-L1 bispecific antibody.
- Public listing: Common stock trades on Nasdaq under the symbol CMPX.
- Employees: 26 employees as of December 31, 2022, including 13 primarily engaged in research and development and clinical activities.
Financial Performance, Liquidity and Capital Structure
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Product revenue | $0 | $0 | No change |
| Research and development expense | $30.0 million | $20.3 million | +$9.7 million |
| General and administrative expense | $11.7 million | $10.9 million | +$0.7 million |
| In-process R&D expense | $0 | $50.6 million | -$50.6 million |
| Total operating expenses | $41.7 million | $81.9 million | -$40.2 million |
| Net loss | $39.2 million | $82.2 million | Loss decreased by $43.0 million |
| Net loss per share | $0.37 | $1.31 | Improved |
| Cash used in operating activities | $34.1 million | $19.7 million | Use increased by $14.5 million |
| Cash, cash equivalents and marketable securities | $186.6 million | Not directly comparable; no marketable securities in 2021 | — |
- Cash and cash equivalents were $34.9 million at year-end, compared with $144.5 million in 2021. Marketable securities were $151.7 million, consisting primarily of corporate bonds, commercial paper, certificates of deposit and asset-backed securities.
- The company had no debt outstanding at December 31, 2022. Its Pacific Western Bank credit facility was repaid and terminated in November 2021.
- Cash used in investing activities was $151.2 million, primarily reflecting $200.1 million of marketable-security purchases partially offset by $49.0 million of sales or maturities.
- Financing activities provided $75.8 million, primarily from the November 2022 PIPE financing.
- The company reported an accumulated deficit of $272.8 million and total stockholders’ equity of $181.6 million at December 31, 2022.
- Interest income increased to $2.4 million from $29 thousand in 2021, primarily because of the company’s larger investment portfolio and higher interest rates.
- Stock-based compensation expense increased to $5.3 million from $4.0 million.
- No meaningful margin analysis is applicable because the company has no revenue and remains loss-making.
Material Changes Versus the Prior Comparable Period
- Research and development expense rose 48%, driven principally by higher clinical, manufacturing and toxicology costs for CTX-009, CTX-471 and CTX-8371. Program spending was $13.1 million for CTX-009, $4.8 million for CTX-471 and $5.6 million for CTX-8371.
- The 2021 results included a $50.6 million in-process R&D charge related to the TRIGR acquisition; no comparable charge occurred in 2022. This was the primary reason the reported net loss declined.
- The company completed a PIPE offering of 25.0 million shares at $3.21 per share, generating $80.3 million of gross proceeds and approximately $75.8 million of net proceeds. Shares outstanding increased to approximately 126.3 million at year-end from 100.8 million.
- The company shifted a substantial portion of its cash into marketable securities, resulting in lower cash and higher current investments.
- Accrued expenses increased to $11.7 million from $8.8 million, primarily because of manufacturing and clinical project expenses. Accrued manufacturing expenses included $6.4 million of minimum contractual obligations for CTX-009.
- Comprehensive loss was $39.5 million, including a $302 thousand unrealized loss on marketable securities.
Development Progress, Outlook and Key Risks
- CTX-009: U.S. Phase 2/3 development continued in biliary tract cancer in combination with paclitaxel, and a Phase 2 monotherapy trial began in metastatic colorectal cancer. In a South Korean Phase 2 biliary tract cancer study, preliminary data as of November 9, 2022 showed a 37.5% objective response rate, 9.4-month median progression-free survival and 12.5-month median overall survival, although the study was small and preliminary.
- CTX-471: The monotherapy Phase 1 expansion study was nearing completion, with three patients remaining as of January 31, 2023. A Phase 1b combination study with Merck’s KEYTRUDA began dosing in November 2022, with an interim data readout expected in the second half of 2023.
- CTX-8371: GLP toxicology and other IND-enabling work was completed in the first quarter of 2023. Management targeted an FDA IND submission in the first half of 2023 and a first-in-human Phase 1 study in the second half of 2023.
- Management expects substantial additional spending as clinical development advances and anticipates continued operating losses for the foreseeable future.
- The filing contains inconsistent liquidity runway language: one risk disclosure states that available resources are expected to fund operations into the second half of 2024, while the MD&A and liquidity footnote state that resources are expected to fund operations and capital expenditures into 2026. The filing does not clearly reconcile the difference.
- Contractual obligations totaled $11.9 million at year-end, including $3.2 million of operating lease commitments and $8.8 million of non-cancelable manufacturing commitments, substantially all due within three years or less.
- The company expects to require additional financing to complete clinical development and potentially commercialize products. Additional equity financing could dilute existing stockholders, while collaborations or licensing transactions could require relinquishing valuable rights.
- Primary risks include clinical-trial failure or delays, adverse events, uncertain regulatory approval, patient-enrollment challenges, reliance on contract research and manufacturing organizations, competition, intellectual-property challenges, reimbursement uncertainty, cybersecurity and data risks, and dependence on key personnel.
- Management stated that disclosure controls and internal control over financial reporting were effective as of December 31, 2022. The auditor did not provide an attestation report because Compass qualifies as an emerging growth company.
- The company is not currently involved in litigation that management believes would have a material adverse effect. It does not expect to pay cash dividends in the foreseeable future.
Most Important Facts for Investors to Verify
- Reconcile the conflicting statements regarding whether year-end liquidity funds operations into the second half of 2024 or into 2026.
- Review the complete cash-burn profile, including quarterly operating cash use, investment maturities and the timing of the next financing requirement.
- Verify whether the preliminary CTX-009 biliary tract cancer results are confirmed in larger, controlled studies and whether they support the contemplated BLA timeline.
- Monitor CTX-471 combination-study interim data and safety outcomes, particularly because the program involves an investigational CD137 agonist.
- Track the CTX-8371 IND submission and FDA clearance, as well as the timing and design of its first-in-human trial.
- Assess dilution from the 2022 PIPE, outstanding options and restricted stock units, and the company’s available at-the-market equity facility.
- Review manufacturing commitments, license milestones and potential royalties, which are not fully reflected in the stated contractual-obligation total.